The case for prostate cancer screening.
Evidence is mounting indicating that screening for prostate cancer is rational and appropriate. More information is necessary to define the optimal ages at which screening should be performed and to determine the appropriate role of PSA, PSA velocity, and PSA density in serial screening. Formal demonstration of a significant screening-induced reduction in cancer-specific morbidity and mortality is necessary to unambiguously justify screening. A prospective, randomized trial evaluating prostate cancer screening will soon be underway.
Andriole
G L
GL
Department of Surgery, Washington University School of Medicine, St Louis, MO 63110.
D000368:Aged; D001706:Biopsy; D003365:Costs and Cost Analysis; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*
D017430:Prostate-Specific Antigen